Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel Welch
AddedMar 19, 2024
UpdatedMay 31, 2026
Daniel Welch

Daniel Welch

Board Member, Ultragenyx Pharmaceutical

CrunchbaseLinkedIn

Daniel Welch's Career

Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical

Novato, CA, US

Board Member· Board
InCarda Therapeutics
InCarda Therapeutics

Newark, CA, US

Board Member· Board
Seagen
Seagen

Bothell, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel Welch's Career

Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Public$789.3M1.3k2010Novato, CA, US
Board Member· Board

Leadership at Ultragenyx Pharmaceutical

Deborah DunsireDeborah DunsireBoard Member
Amrit RayAmrit RayBoard Member
Clay SiegallClay SiegallBoard Member
Marten SteenMarten SteenBoard Member
Shehnaaz SulimanShehnaaz SulimanBoard Member
Matthew FustMatthew FustBoard Member

Similar to Ultragenyx Pharmaceutical

PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Amicus TherapeuticsAmicus TherapeuticsCranbury, NJ, USBiopharmaceuticalsest. 2002Amicus TherapeuticsCranbury, NJ, US · est. 2002

Amicus Therapeutics, a US-based public biopharmaceutical company, specializes in innovative medical solutions.

Public · $2.4B484
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
InCarda Therapeutics
InCarda Therapeutics
Series A$86.4M102009Newark, CA, US
Board Member· Board

Leadership at InCarda Therapeutics

Norbert BischofbergerNorbert BischofbergerBoard Member
Gregory M. MarcusGregory M. MarcusCo-Founder
Adam FreundAdam FreundCo-Founder
Narsi RangachariNarsi RangachariCo-Founder
Robert LisickiRobert LisickiCEO
Carlos SchulerCarlos SchulerCo-Founder

Similar to InCarda Therapeutics

Cardeas PharmaCardeas PharmaSeattle, WA, USAntibiotics, Pharmaceuticalsest. 2010Cardeas PharmaSeattle, WA, US · est. 2010

Cardeas Pharma: Specializing in developing inhaled antibiotics for respiratory infections.

Series B · $80M30
BioCardiaBioCardiaSan Carlos, CA, USMedical Devices, Therapeuticsest. 1999BioCardiaSan Carlos, CA, US · est. 1999

BioCardia, a San Carlos-based medical firm, develops innovative regenerative therapies for critical cardiovascular diseases.

Public · $41.3M28
Respira TherapeuticsRespira TherapeuticsAlbuquerque, NM, USDrug Delivery, Inhalationest. 2010Respira TherapeuticsAlbuquerque, NM, US · est. 2010

Respira: A drug delivery tech company specializing in efficient dry powder inhaler technologies.

Series B · $5.1M9
Cardurion PharmaceuticalsCardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $343.1M42
Seagen
Seagen
Public$1.7B3.3k1997Bothell, WA, US
Board Member· Board

Leadership at Seagen

David GryskaDavid GryskaBoard Member
David R EpsteinDavid R EpsteinBoard Member
Ted LoveTed LoveBoard Member
Felix BakerFelix BakerBoard Member

Daniel Welch's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Daniel Welch

George BickerstaffGeorge BickerstaffBoard Member · InnovivaDavid ChazanovitzDavid ChazanovitzBoard Member · Inovise Medical